Tenaya Therapeutics, Inc.

Equities

TNYA

US87990A1060

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.31 ^USD	+2.13%		-0.23%	+33.02%

Mar. 20	Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $18 From $19, Maintains Buy Rating	MT
Mar. 19	North American Morning Briefing : Stock Futures -2-	DJ

Tenaya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 08, 2023 at 04:34 pm EST

Tenaya Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 123.67 million compared to USD 72.72 million a year ago. Basic loss per share from continuing operations was USD 2.76 compared to USD 4.1 a year ago.

Latest news about Tenaya Therapeutics, Inc.

Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $18 From $19, Maintains Buy Rating	Mar. 20	MT
North American Morning Briefing : Stock Futures -2-	Mar. 19	DJ
Tenaya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Tenaya Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 18	CI
Tenaya Therapeutics, Inc. Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine	Mar. 18	CI
Transcript : Tenaya Therapeutics, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 08:40 AM	Mar. 12
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications	Feb. 26	CI
Tenaya Therapeutics Insider Bought Shares Worth $9,999,999, According to a Recent SEC Filing	Feb. 14	MT
Tenaya Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Tenaya Therapeutics Gets FDA Clearance For TN-401 Gene Therapy Trial	23-10-26	MT
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy	23-10-26	CI
Tenaya Therapeutics, Inc. Releases New Data for Tn-301 At the 2023 Heart Failure Society of America	23-10-09	CI
Tenaya Therapeutics Doses First Patient in Early Stage Trial of Heart Disease Gene Therapy Candidate	23-10-05	MT
Tenaya Therapeutics, Inc. Doses First Patient in the MyPeak-1? Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy	23-10-05	CI
Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $17 From $18, Keeps Buy Rating	23-08-11	MT
Morgan Stanley Adjusts Price Target on Tenaya Therapeutics to $14 From $13, Keeps Overweight Rating	23-08-10	MT
Tenaya Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Tenaya Therapeutics Inc Provides Information to Shareholders	23-06-12	CI
Chardan Trims Price Target on Tenaya Therapeutics to $23 From $24, Maintains Buy Rating	23-05-12	MT
Tenaya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Tenaya Therapeutics Says US FDA Grants Fast Track Label for Heart Disease Drug Candidate	23-05-02	MT
Tenaya Therapeutics Gets FDA Fast-Track Designation for TN-201	23-05-02	DJ
HC Wainwright Adjusts Price Target on Tenaya Therapeutics to $18 From $25, Maintains Buy Rating	23-03-09	MT
Chardan Cuts Price Target on Tenaya Therapeutics to $24 From $28, Keeps Buy Rating	23-03-09	MT
Tenaya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-08	CI

Chart Tenaya Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Companyâs advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Companyâs adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.31 USD

Average target price

19.43 USD

Spread / Average Target

+350.78%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TENAYA THERAPEUTICS, INC.	+33.02%	338M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+48.04%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research